Notable Labs, Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTBL research report →
Price Chart
About the company
Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug.
- CEO
- Kaile Zagger
- IPO
- 2014
- Employees
- 16
- HQ
- Or-Yehuda, IL
Get TickerSpark's AI analysis on NTBL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.39M
- P/E
- -0.05
- PEG
- -0.00
- P/S
- 7.72
- P/B
- 0.04
- EV/EBITDA
- 0.51
- Div Yield
- 0.00%
- Gross Margin
- 36.45%
- Op Margin
- -4728.06%
- Net Margin
- -3633.55%
- ROE
- -59.97%
- ROIC
- -84.60%
Latest fiscal year · YoY change
- Revenue
- $310.00K+3775.0%
- Gross Profit
- $113.00K+109.8%
- Op Income
- $-14,657,000
- Net Income
- $-11,264,000+21.8%
- EPS
- $-5.03+22.6%
- OCF Growth
- -17.8%
- FCF Growth
- -18.0%
- 52W High
- $4.24
- 52W Low
- $0.22
- 50D MA
- $0.47
- 200D MA
- $0.92
- Beta
- -2.36
- RSI (14)
- 23
- Avg Volume
- 2.57M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
VBL Therapeutics said it remains on track for a second-half 2022 OVAL PFS readout, while highlighting Fast Track status for ofra-vec and early progress on VB-601.· May 17, 2022
- OVAL Phase 3 enrollment is complete with 409 patients, and top-line progression-free survival data are still expected in the second half of 2022.
- The FDA granted Fast Track designation for ofra-vec in platinum-resistant ovarian cancer, which management said could help expedite development and review.
- Two additional ofra-vec studies in metastatic colorectal cancer and glioblastoma remain ongoing, with preliminary data expected later in 2022.
- VB-601 is moving toward first-in-human testing after pre-IND feedback and completed toxicology studies supported clinic entry.
- Quarterly spending rose as OVAL activity increased, but the company said its $44.8 million cash balance should fund operations for at least 12 months from the OVAL top-line readout date.
For Q1 2022, revenue was $0.1 million versus $0.2 million in Q1 2021. Total operating expenses were approximately $10.7 million, up from $6.5 million a year ago, including $7.5 million of R&D and $3.2 million of G&A. Net loss was $10.4 million, or $0.13 per basic share, compared with a net loss of $6.3 million, or $0.12 per basic share, in Q1 2021. Cash, cash equivalents, short-term bank deposits and restricted bank deposits totaled $44.8 million at March 31, 2022. Management said this cash should fund planned operating expenses and capital expenditures for at least 12 months from the date of the OVAL top-line PFS readout, expected in the second half of 2022.
Dror Harats framed 2022 as a promising year driven by late-stage clinical milestones and said the company is on track for the OVAL PFS readout in the second half of the year. He emphasized that a positive PFS result could be transformative and could support a BLA filing in the first half of 2023. He also highlighted Fast Track designation, the ongoing colorectal and GBM studies, and VB-601’s advance toward the clinic as evidence of a broader pipeline.
Sam Backenroth focused on the quarter’s financials and runway. He reported $0.1 million in revenue, $10.7 million in operating expenses, a $10.4 million net loss, and $44.8 million in cash and deposits at quarter-end. He said spending should normalize somewhat after the heavy OVAL-related quarter, while pre-commercialization work and preparation for a first-half 2023 BLA filing will continue. He also said none of the €17.5 million discussed in Q&A was included in the March cash balance and that both the grant and equity portions are expected in the coming months.
Analysts asked about the timing and composition of the €17.5 million cash support; management said none of it was in the Q1 cash balance and that the grant portion and equity portion are both expected in the coming months, with the equity slightly behind. Questions on ASCO posters and OVAL updates were met with limited disclosure because the data are embargoed and the trial is randomized and double-blind. On OpEx, management said Q1 was heavier due to OVAL activity and data cleaning, but spending should normalize somewhat over the year. Payer discussions for a potential ovarian cancer launch were described as favorable, with management saying payers viewed pricing for the drug as reasonable given the dosing schedule and unmet need.
The positive case is centered on OVAL: enrollment is complete, DSMC review was favorable, and management still expects the key PFS readout in the second half of 2022. Fast Track designation could streamline development, and management believes a positive PFS result could support a BLA in early 2023. Beyond ovarian cancer, ongoing colorectal and GBM trials plus the VB-601 inflammatory program give the company multiple shots on goal.
The main risk remains binary clinical execution, since the company said it will not disclose more OVAL detail before the readout and the outcome is still unknown. Revenue is minimal, while operating expenses and net loss increased year over year, underscoring continued burn. The business also depends on future financing or external support, including the €17.5 million package that had not yet been recognized in cash at quarter-end.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 21.4%
- Shares Outstanding
- 9.66M
- Float Shares
- 2.07M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 24 | Zagger Kaile A. | other | 0 |
| May 8, 24 | Patsi Tuomo | other | 65,247 |
| May 8, 24 | Wagner Joseph P | other | 200,000 |
| May 8, 24 | Galen Michele | other | 40,247 |
| May 8, 24 | DUBIN THOMAS I H | other | 40,247 |
| May 8, 24 | Graney Thomas | other | 40,247 |
| May 8, 24 | Feinberg Peter | other | 40,247 |
| May 8, 24 | Bock Thomas | other | 400,000 |
| May 8, 24 | Bock Thomas | other | 150,000 |
| Jan 24, 24 | Feinberg Peter | other | 9,753 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NTBL coverage
Recent articles, reports, and earnings notes.
No research on NTBL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NTBL report →Notable Labs to Present Data on September 4th at SOHO 2024
globenewswire.com · Aug 29
Notable Labs Announces CEO Transition
globenewswire.com · Aug 26
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now
zacks.com · May 24
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
globenewswire.com · May 9
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Apr 19
Notable Labs Reports 2023 Financial Results and Provides a Business Update
globenewswire.com · Apr 12
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
globenewswire.com · Apr 9
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
globenewswire.com · Apr 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.